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REPORT ON TECHNICAL CONSULTANCY AT FEDERAL VACCINE 
PRODUCTION LABORATORIES/ YELLOU FEVER VACCINE PRODUCTION, 
YABA. LAGOS. NIGERIA.
Ref: Yellow Fever (Nigeria) T-87-073 
Period of consultancy: October 4 - 19, 1987
Place: Federal Vaccine Production Laboratories, Yaba, 
Lagos.
1 “ Objectives of consultancy:
~ evaluation of local Yellow Fever/Yellow Fever Vaccine 
Product i on.
discussion on details of vaccine production.
discussion on the requirements of material and training 
in order to upgrade the YF facility.
assistance to the Federal Vaccine Production Laboratories 
(FVPL) in the preparation of proposal of a Project for 
modernization and upgrading of YF Vaccine Production, 
Yaba, for IDRC submission.
2 - Contacts made during the visit:
Professor Ransone - Kuti, Federal Minister of Health, 
Federal Ministry of Health, Ikayi, Lagos.
- Mr. A. Larval, Permanent Secretary, Federal Ministry of 
Health, Ikoyi, Lagos.
Dr. Gaby Williams, Director, Public Health Services, 
Federal Ministry of Health, Ikoyi, Lagos.
Dr. Brew - Graves, WHO Representative in Nigeria, Federal 
Secretariat, Ikoyi, Lagos.
Dr. A.B. Suleman, Director of National Health Planning, 
Federal Ministry of Health, Ikoyi, Lagos.
3 - Contacts and technical discussions have been hold with 
the following professionals of Federal Vaccine Production 
Laborator~ <FVPL>, Yaba, Lagos: 
Dr. A. Nasidi, Consultant Virologist, Head of FVPL. 
Dr. G. M. R. Munube, WHO Virologist Consultant. 
Mr. A. 0. Rufus, Chief Medical Laborator~ Technologist. 
Dr. C. B. Coker, Head, of Qualit~ Control Unit. 
Mr. 0. Oduto~u. Head, of Administration Office. 
Mr. J. J. Ozogula, Head, Experimental Animal Un)t. 
Mrs. M. E. Edozien, Head, Yellow Fever Vaccine Production. 
Mr. S. S. Olu~ode, Head, Rabies Vaccine Production Laborator~ 
Mr. S. A. Musa, Head, Maintenance Unit. 
Miss Owokoniran, D. Head, B.C.G. Vaccine. 
Mr. S. A. Egbewunmi, Diagnosis of AIDS. 
A schematic chart of structure of FVPL is attached (annex 1). 
4 -To enable the accomplisliment of te~hG ~al consultanc~, 
Dr. A. Nasidi, the head of FVPL has introduced me to the 
staff members and has asked them to provide me with 
information requested to enable a proper evaluation of YF 
vaccine product ion and control. Several meetings with 
specific groups and the visiting to the laboratories were 
them made. 
There are two main FVPL laborator~ compounds. The Central 
compound obrigates the direction of FVPL and laboratories 
of Qualit~ Control, comprising the laborator~ of 
experimental animal for YF vaccine potenc~ determination, 
sterilit~ and chemistr~ control. There are several other 
laboratories for diagnosis and surveillance of YF, 
Hepatitis, Measles and AIDS, and the laborator~ for 
anti-rabies vaccine production. 
The laborator~ of Qual it~ Control, besides doing the final 
control of YF vaccine produced at FVPL, anal~ses imported 
YF vaccines and the vaccines used in EPI vaccination. 
The laborator~ facilit~ of Qualit~ Control, at the time of 
visit, was undergoing changes and re-organization. To The 
laboratories, is being provivided better accomodations. 
The basic equipments required for control were positioned 
at place and apparentl~ are functioning. 
Some of the last lots of YF vaccine titrated 
section is attached as annex 2; none of YF final 
tested for bacterial sterilit~ was positive. 
in this 
product 
It was possible to see the results of testing in the 
protocols positioned in each laboratories. 
Ver~ recentl~, during YF mass vaccination 
sera-conversion stud~ was performed b~ Center 
Control/CDC, using YF vaccine produced at FVPL, 




The virolog~ groups are preparing themselves to go into 
tissue culture technologies and rna~ be able to titrate 
Yellow Fever Vaccine in tissue culture in near future. 
5 The Yellow Fever Vaccine is produced in the second 
compound which is about 1,5 km apart from central compound, 
is formed b~ several buildings: 
Laborator~ for Yellow Fevr Vaccine 
breeding, Rhesus monke~s colon~, B.C.G. 
maintenance workshop. 
production, 
labor at or~ 
mice 
and 
The Yellow Fever Laborator~/YFL was constructed in 1948 and 
originall~ was planned for a Hospital. It was adapted for 
YFV production and started this activit~ in 1952. The YFL 
comprisis 280 mlof area. 
Although is newl~ painted, the facilit~ is old and requires 
several improvements and critical modernization. 
The YFL is organized comprising the following areas: 
a) washing, preparation and sterilization, distilation of 
water; 
b) steril area, provided with barrier (air-lock s~stem> and 
an area for sterile cloth changing. The operations of 
eggs inoculation, embr~o havesting, ernbr~o homogenizing 
and macerating, collection of pulp, centrifugation, 
collection of ernbr~o Juice and filling are processed in 
this room. This area in well painted and ver~ clean; 
c) freeze-dr~er room, next to sterile area; 
d> freezer room; 
e) experimental animal room; 
f) chemistr~ room: for media preparation and sterilit~ 
control. The incubation for eggs is placed in this 
laborator~. Next to this room, in a small room the virus 
dilution for mice titration is ~ade; 
g) Head Office; 
h) Apart from main building are: laundr~ house, generator, 
incinerator, store house and maintenance workshop. 
i) Office for senior staff and room for Junior staff. 
The basic equipment required for production are positioned 
and are functioning, although most of them are ver~ old and 
replacement parts are not available. To the most of 
equipments which requires temperature, vaccum or pressure 
recording, the register are attached but out of order. A 
list of existing equipment and its functioning status, 
prepared b~ the maintenance team is attached as annex 4. 
& Procedures of YF Vaccine production 500 fertile eggs, 
brown, shell, supplied b~ a private local poultr~ firm are 
inocubated weeki~. There are about 15X of loss among 
crushed and infertile eggs. 
The seed-virus was received from Wellcome Laboratories in 
1961 <annex 5). The inoculation is made on the amniotic 
membrane in 8 da~s old chickem embr~o. After 4 da~s of 
incubation the harvest of embr~o is performed. 25 embr~o 
is collected in each blender-Jar and 75 ml of phosphate 
buffer is added and homogenized. Thereafter, the pulp is 
collected, sheelfreezed and stored at -70 C. At this stage 
a sample is collected for sterilit~ control and potenc~ 
test. A ver~ few contamination is observed, as it was 
registered in the protocol book. In the annex 6, 7 and 8 
some further informations of their production are showed. 
When the sterile control and potenc~ testing are read~. 
enough quantities of pulps are thawed, centrifugated and 
embr~o juice collected and pooled. A sample is again taken 
for sterilit~ and potenc~ testing. The pooled juice is 
splited in vials for freeze-dr~ing, which is processed in a 
48 hours c~cle. 
The vaccine is produced in 10, 20 and 40 doses 
presentation. A table with results of last 10 batches is 
attached as annex 6. 
The current schedule for YFV production is established as 
follows: 
a) at Wensda~s: eggs incubationJ 
b) at Thursda~s: eggs innoculation; 
c) at Monda~s: embr~o harvesting; 
d) at Tuesda~s: lioph~lization. 
This work-schedule 
vaccine production 
the current ~ear. 
is being operational. As result the 
has augmented a ver~ much <annex 7) in 
The head of Laborator~ Ms. M. E. Edozian has 15 ~ears of 
experience in YFV production. She is graduated in biolog~ 
sciences and is specialized in bacteriolog~. The Assistant 
to head Mr. J. J. Ozogula, principal technologist, has 
been working 16 ~ears in vaccine production and 10 ~ears in 
YFV production. Other members of technical staff seens to 
have also good laborator~ skills but if the~ receive some 
more support such as specific training courses, should be 
able to colaborate and participate intensivel~ in the 
modernization and upgrading project. 
The leaflet of YF vaccine, Yaba, Lagos is attached as annex 
8. 
7- Althoygh the YFV laborator~ is operating roytinell~, 
several important constraints exists, as follows: 
the washing and sterilizing capacit~ is ver~ small; 
the sterile area is ver~ small; 
the flow of prodYction presents several crossing points; 
the freeze-dr~ers are of small capacit~; 
the maintenance staff members are not specialized and are 
not part of prodYction team; 
the short-cYrt of power occYrs almost ever~ da~, even 
thoYgh the~ have back YP generators; 
the supplies, glassware and spare parts are not enoYgh; 
financial constraints, particYlar~ 
bydgest is ver~ low. 
the rYning cost 
8 -After several meetings and discYssions with FVPL staff 
members, with active participation of the Head of FVPL, Dr. 
A. Nasidi and WHO virologist consyltant, Dr. :. M. R. 
Munube the following docyments were prepareand are attached 
as annex 9: 
a) the outline of the project for modernization and 
ypgrading YFV prodyction, Yaba; 
b) preliminar~ drawing for the modernization and ypgrading 
YFV prodYction laborator~; 
c) alternative la~-oYt for right wing. 
d) preliminar~ drawing for dilYent prodYction. 
e) cYrrent la~-oYt of YFV prodYct ion laborator~. 
The FVPL will fill the IDRC application form Ysing 
outline of the project attached, and will send it 
IDRC/Regional Office for Africa in Senegal/Dakar, as 




To make possible further steps towards the modernization a 
private especialized firm was contacted and arragments is 
being made for the preparation of engineering project. 
According to the Ministr~ oi Health authorities this is a 
priorit~ project and a special budgest will be alocated to 
make possible the execution oi YF laborator~ modernization. 
9 As Nigeriam Ministr~ of Health is planning a new 
complete center for vaccine production needed for EPI in 
Abuja, the new capital of Nigeria, this proJect could be 
ver~ important, as additional motivating factor b~ 
functioning as demonstration project of Nigeriam biological 
technolog~ capabilities. 
10 - These documents were also presented to the Minister of 
Health Professor Ransome-Kuti, to the Permanent Secretar~ 
Mr. A. Lawai and to Dr. Gab~ Williams, Director of 
Public Health Services. A strong committment from all 
above authonltes of Ministr~ of Health was obtained to 





PBDDAL YACCID PRODUCTIOJt LABORA'l'ORI:IS, 
Y.AM, LAGOS, lllGERU. 











~ .Senior .Staff 





1 ... syJ.LJ 
on----n"an 










Dr. Coker s7 1 Jt2 
Exp.S2/t6 
Animal ~ 


















YYV • 59} 
T 7l _._ _52 4 
ll'V • 295_ 
YFY • 596 
YFV • 597 
IFV • 599 
Tn • 6o1 
TJ'V • 60} 
TYV • 605 
YFT • 607 
T1'T • 609 
§0Jf.F. YELLOw Fi;Vl!Ji VACCIN~-S 
1- :.c-~.lVl.D .n.NT1 ':T3E~1 ?Y 'T:!l 
Q'U ALI 'fY CC.'l''fit OL u F I 'I' I Fi.~.LJ :.Ji ~ L 
TAOCI~~ PRODUCTION LA30hh~ORIES 
. . 
:BY ANIJ'..A.L 
~IGUi DA'I'E Tr:S'f&D 
l!'IC>OUL;.TION 
TITRE LDSO _.,.,... ______ 
.FVPL Lf5o"'937/o.sml 
La.goa :n.·eria 28/1/87 buma.n dose) 
2BL1/f1J 
LD50=356J/0.5ml 
FYPL (human dose) 
2_4}2 187 
LD50=1442/0.5ml 
F'VPL (human dose) 
6/:. 'S7 
LD50 ... 10~7/0.5ml 
?\'TL ( :bu...:a.n d c s e _)_ 
LD50=}7~2/per 





F'fPL {human dose) 
25/6/87 
Ll>50=4807/0.5al 
}I'VPL {human do~e} 
LD~0,.,2645/0.Sml 
YVPL 25/6/87 (hl.lln&n dose 
19/8/87 
L450=1913/0.5al 
.FYPL (huaan dose) 
20/8/87 
LD50s}811/0. 5al 

















1 YfPL (huma.n dose) ~.22 Goo4 
DR. A. Y. ~asidi-Cone~ltant Virologiat. 
DR. c. B. Coker-Principa.l Tirolo~ist • 
Dl. Runube - WHO Cons•ltant Virologist • 
~0'~-_.., 
s. o. Johnson 
Scientific Officer • I. 
AN~EX 3 
DLP.\R1\1f:.~1 CJf HLA.LTH & HL'\1A~ SERVICES 
C e n t e r f o r 1 n f l' c t i cn1 s J) i s c a s e '' 
Division of Vector-Horne Viral Diseases 
P. C!. 3ox 2087 
fort Collins, Cu b0~L2-2Uo7 
(3uJ) .::L1-b4::8 
Ja!iuary 23, lYb7 
Dr. A. ~asidi 
Consultant Virologist 
Federal Ministry of Health 




Dear Dr. Nasidi: 
·we have COiupletea neutralizat~on tests on toe cnilaren bled on lg December, 
1986. These children had been vaccinated on 31 October, 1986, with Yaba 
vaccine ( expiration date, October 1986). Fifty-three sera were obtained; two 
sera .. ·ere missing (blood may not have been obtained from these children). Of 
the 51 sera tested, 50 (98%) had detectable yellow fever neutralizing 
antibodies. Four children had low titers ( 1:2) or insufficient serum was 
available to test at higher dilutions. 
The seroconversion rate in this population is excellent and consistent with 
previous studies which generally show 95% or greater rates after 
administration of 17U vaccine. 
The seronegative child (No. 263, Lydia Otiyunge) should be re-immunized. It 
would not be unreasonable tore-immunize the 4 children with titers of 1:2, 
although they are probably protected. 
Warmest personal regards, 
TPM: dgl 
cc: Dr. ~evin DeCock (With Table) 
Dr. Bruce Cropp (With Table) 
Sincerely yours, 
.... 
/ I o ¥\->.._ 
Thomas P. Monath, M.D. 
Division Director 
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BATCH SEED VIRUS PULP TITRE EMBRYO FREEZE DRY 
NO TYPE JUICE TITRE TITRE 
590 to-1·';o.03•1 1t-4,0 10_3.07 
10-2.46 
333,LD/50 333,333 LD/so 39,ooo LD/so 
4,87. LD/50 
per egg/0.125m1 per a1 (5.52ml) per ml (4iml) 
per dose (40) 
ml 
591 1o-2.88 10-•·o 10_3.92 1Q-3.40 
851 LD/5o 333,336 LD/so • 277,21i W/50 41,85i LD/50 
per eqg/0.125m1 per •1 (5.52ml) per al (5.44) per dose ( ~ 2a1) ! 
ml I 
592 1Q-2.i 10-•·5 te-4.1i 
10-3.47 
: 1658 LD1so 1,054,000 •481,66i LD/~iO 52,701LD/50 
per egg/0.125•1 
LD/so per ciose s.02al) 
per m1 (6.02m1) per Ml ( 5.i8a1) 
10-4.24 10-3 •• 7 593 10-2.75 to-4-32 
577,33U>Iso 49,183LD/so • 2343 LDfso i96,333/LD/so 
- per egg/0.125•1 per •1 ( 5 • 84) 
per ml (5,76ml) per dose (4.99al) 
•1 
594 1o_10-2.75 10-s.o 10-4.11 10-3.31 
2343 LD/so 3.3 X 106 LD/50 • 500,6iiLD/50 3.,029LD/50 
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FREEZE-DRIED 170 YELLOW FEVER VACCINE FOR 
SUBCUTANEOUS USE 
GENERALINFORMA TION 
This vaccine is a live, attenuated freeze-dried (lyophilized) product 
prepared from an extract of chick embryos inoculated with 1 7D strain 
of yellow fever virus. The v•als are sealed in the atmosphere of dry 
nttroger gas. The vaccine tS sensittve to heat and light and must. there· 
fore. be stored according to imtructions. It is used for protection agatnst 
yellow fever. 
2. INDICATIONS 
For protect.on against yellov. fever in endemtc areas or during 
yellow fever epidem.cs 
As a requirement for internation travel. 
3. CONTRA-INDICATIONS 
4. 
Sensitivity to egg proteins, generalized malignancies, immuno-supressive 
states whether in-born or acquired, severe febrile illness, pregn<mcy, 
infants under 12 months of age except in the face of an epidemic when 
infants 6 months and over may be vaccinated. 
PRECAUTIONS/WARNINGS 
A 1:1000 epinephrine (adrenaline) should be available when giving 
vaccines in case anaphylactic reaction develops. 
5. ADVERSE REACTIONS 
Except for ar.aphyiactic reactiOn in :ndividuais sensitive to egg protein or 
those with above-mentioned contra-indications, adverse reactions to 170 
yellow fever vacctne are extremely rare. 
6. DOSAGE AND ADMINISTRATION 
(a) Warning 
Aseptic measures must be taken tn any of the steps leading to the 
administration of the vaccine. The vials must be examined carefully 
and broken or ccacked ones should be discarded. Expired vaccine 
should not be used. 
(b) Reconstitution 
For ~econstitution of the vaccine, use the recommended, chilled 
diluent in volumes consonant with the doses in the vials (2.5ml for 
5 doses. 5 5mi tor 10 doses, 11 ml tor 20 doses, 27m I for 50 doses). 
Keep the reconstituted vaccine on wet ice or in a refrigerator at 
(+2-B=C) unti: all doses have been used. In any case, the reconsti· 
tuted vaccine should be used within one hour. Any volume of the 
vaccine that remains after each vaccination session shouid be 
discarded on the same day. 
(c) Dosage 
The humaf' dose for batt-> children and adults of the reconstituted 
vaccine is 0.5ml given subcutaneously over the deltoid area of the 
arm. 
A ~~>< 9-CL 
Project Title: Modernization and Expansion of the Yellow Fever 
Vaccine Laboratory, Federal Vaccine Production 
Laboratory, Yaba, Lagos, Nigeria. 
Project Leader: Dr. A. Nasidit 
Federal Vaccine Production Laboratories, 
Yaba, Lagos. 
SUJ.1M.\RY 
Yellow fever, an acute viral disease, is still a troubleson'!e public 
health problem in the tropical area of Africa. Periodically recurring 
epidell"ics cause thousands of cas~s and deaths as evidenced by the 
recent outbreaks of the disease in Nigeria. Besides, vaccination to 
control yellow teNer epidemics, the Flideral Ministry of Health has 
strongly committed itself to the inclusion of yellow fever vaccination 
in the Ex:pa.ndtd Programme on x-misation as a measure of increasing 
herd innunity of the population in the coming years. 'l'he demand of 
the yellow fever vaccine will consequently markedly increase. The 
Federal Vaccine ProductJon Laboratory, Yaba, Lagos is embarkinq on 
aeasures towards lllOClernization, upgradir19 and strengthening the 
capabilities of production and quality control so that the vaccine 
produced will satisfy all the WHO mint.um requirements especially those 
related to thermostability. 
The moc:lernization and upgrading project includes improvement of the physical 
facilities, provision of new equipment and supplies and the training of staff. 
The ex6ution of the project will require external assistance to supplement 
the effort of the Federal Ministry of Heal.th of the Federal Republic of 
Nigeria. 
When the project is fully implemented, Nigeria will be self-sufficient in 
high quality, thermostable yellow fever vaccine and could even be in a 
position to supply vaccine to other needy countries in the region. 
The reorganization of the present Federal Vaccine Production Laboratory, 
Yaba will require a serious investment, as detailed in the proposal. 
SACKG:::<.CU!-lD 
1. Yellow Fever is an acute infectious disease caused by a virus transmitted 
to humans by mosquitoes. The virus is maintained in nature by monkey-
mosquito - monkey cycle. The main clinical features include fever, jaundice 
and haemorhagic manifestation. During epidemics, the case fatality rate has 
been observed to range from 20-80%. Deaths are usually associated with 
renal, hepatic or cardio-vascular failures. In the absence of an effective 
treatment, the only available method of aanagement is the administration of 
symptomatic treatments. 
2. In Africa, outbreaks or epidemics of Yellow Pf!Ner (lf) occur periodically 
in endemic areas, stretching from latitude tSON to 100s. Countriea lying 
between these lati tutes have experienced more than one epidenic of 'Xf' OYer 
the last 50 years, each epidemic being associated with high death rate. 
For example, 1n 1960-62 a very serious epidemic involvi.ng 100,000 people 
with an estimated 30,000 deaths, wu aperimced 1n Ethiopia. In Welt 
African Countries, similar serious epid.Ucs have oec:.urred in countri• 
like Senega1(1965-20,000 c:aaes/6,000 deaths), Nigeria(1969-10,000 cu•/ 
4,000 deaths), Gambia(1978-?9 - 8.400 caau-1,600 deatha), Burkina Pasao 
(1983-25,000 c:asea-1,400 deaths) and aqain 1n 1Cigeria(1986-87 estimation 
50,000 cases with 12,000 deaths). Obviously, there are ld.nor outbrealaa 
in between these biq epidemica which occur without attracting the attention 
of the Public Health Authorities. 'l'he fiqur• presented above do not, moat 
probably represent the true picture of cases and 4eatha that do oc:cur clurinq 
these epidt!!ldca, but are howenr sufficient to depict the qrari.ty ot the lP 
situation in Africa. 
3. In JROSt of the YF epidemics recorded in Africa, the following apec:i• of 
Aedes mosquitoes have been incriainated in the tran•iuion of the cliseuea 
naaely Aedes afric:anus, Ae, lutheoc:eelua. Ae. fuld.ter/taxlo.rJ:.Ae. !i!pal. 
Ae! aeqypti, etc. In addition, AI• aeaypfii, the urban vector of lP can be 
found in many villages and towns. During the recent !F epideaic in Nigeria 
( 1986-87) in Oju, Benue State and Ogoja, Cross River State, the aain IIDIJquito 
vector was founcl to be Ae. africanus. However, in the oyo epi~(April­
October, 1987). Ae. aegxpti was the only vector involved. 
4. The main approach for the prophylaxia of yellow fever, besides the vector 
control in the urban area, is the vaccination of susceptible population. 
There is an excellent vaccine against yellow fever, which seed virus 
strain and technology was developed in the early thirties by the Rockefeller 
Foundation. Basically, it consists of infecting growing chide: embryo with 
attenuated virus( 170 strain) and recovering of vaccine virua fraa embryo 
tissues. The vaccine D.lst be freeze-dryed because of its easy and rapid 
thermo degradation. 
In the laat ffi!W years the technology of Yellow Fever Vaccine Production 
has been very Dlch improved. It involves the use of a well defined chide 
embryo( like SPF eggs), the thermo stabilisation of vaccine, ac»ption of 
Good Manufacturing Practices(GMP) and Minimal Requirem•ta doo.aented in 
the Technical Report Series and other related publications of the World 
Health Organization, which include high standards of laboratory facilities 
for both production and quality control. 
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5. It is known that the Yellow Fever Vaccine is one of the safest and most 
effective vaccines available. A single potent ~se of this vaccine is 
enough to provide protection to the vaccinee for at least 10 years, if 
not for life. Despite the availability of such a safe and effective 
vaccine against this disease, the epidemics continue to be experienced 
in a number of African countries, including Nigeria. This is largely 
due to the absence of well-defined, prophylactic vaccination progranaa 
•r policies. Mass vaccinations are only carried out in response to 
epidemics. Such approachea, apart from being expensive in terms of 
human, material and financial resources, do not provide long tel'lll 
solution to the problem. 
The absence of a national policy on regular vaccination against D' in 
Nigeria has contributed to the \Dlder developnent of the available 
facilities for the production of Yellow Pever Vaccine(YPV) in the 
Federal Vaccine Production Laboratory(P'VPL) Yaba, Lagos. 
6. The Federal Vaccine Production Laboratory( FVPL) was created from the 
Rockefeller Yellow Fever Laboratory, Vhich was established in 1925. 
In the early 1930s the Laboratory started produc::1ng smallpox vaccine 
in sheep. This Laboratory contributed enormously towa.rda the total 
eradication of smallpox in West Africa. The prociucUon of Anti.....cabiea 
vaccine(ARV) was startecl in 1948, and the vaccine was producecl in sheep 
brain using the Semple methodology. Presently, the Laboratory producea 
an average of 25,000 doses of ARV for huaan use anmaal.ly. The aethod of 
production ensures c:omplete inactivation of virus using phenol. 
In 1952, the production of YF waa started; and by 1.956, the locally 
produced vncc:ine was approved by the WHO. Presently the annual p.roduc:tion 
eapac:ity is about 1,200.000 doses. 'l.'he actual annual average productiODJ.wel 
for the last 1.0 years has been about 1.20,000 closes per year. Such low 
level of produetion is caused by sseral constra.inta. However, produc:tion 
of 500, 000 dollea is being attained this year just by the introduction of 
an effective managerial system. 
7. In addition, the FVPL provides important laboratory support for crucial 
public health progrmrmes such as the surveillance and diagnosis of viral 
diseases(YF, hepatitis, measles and AIDS) and the monitoring of the 
potency and efficacy of Expanded Programme on Immunization(EPI) vaccines. 
s. 
The World Health Organization has been actively associated with the 
activities of the(FVPL) for several years through the provision of 
technical and professional personnel and certain equipaenta and materialae 
This collaboration is continuing and presently a WHO Consultant Virologist 
is attached to the FVPL. 
The present FVPL administration has been able to obtain 1ncr:eased 
encouragement and support from the Federal Minister of Health to the 
effect that concrete measures have been initiated towards the up.-grading 
and expansion of the Yellow Fever Vaccine Laboratory(XFVPL). For example, 
money was made available for the regular supply of ferUle eggs on annual 
basis as against the former supply system, based on ad hoc arrangements. 
Money was also made available for the procurement of a large quantity of 
vials, rubber stoppers and aluminium caps, required to cover a long 
period . of ~rod:'ction. . These devel~pment~ ~ve enabled. th~ achi(W ~ r t of - - -. ~ - .-.... -·~ 
~eased. level~- production by aoout-5 times. Tlaia shows ·t!hat there is 
a capable Techni.C<tl staff at the Federal Vaccine Production Laboratory 
whidl coW.d be put to greater use, if the facilities were fully supported, 
modernised and up-graded. 
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The reorganisation of personnel and creation of some additional units in the 
~lity Control Section, has contributed to the attaimaent of better perfor-
.ance. 
9. Because of the recent large epidemics of YF in the country, the authorities 
of the Federal Ministry of Health are stroogly COIIIIIli.tted to include the 
'ACCinatiOD aqa!nllt. Yellow Penr in the EPI which today includes OPV,Meailes 
and Dft .accinat.ion. '1'b1a hu bee a~ed. by the Federal Min.i.ster of Health 
and ad.opted u a policy. Several experta, including those frca the World 
Health Organisation, who studied the recent Nigerian Yellow Fever outbreak 
pr:oduced acae illportant documents, in which the inclusion of YPI 1n the EPI 
was alao str0119lY recoaaend.ed. 
The inclusion of YFV in the EPI will neceuitate an annual requirement of 
5 to 6 Jl1111an doses of !F vaccine (Nigeria's annual birth rate:4.5 million 
infants>. 
10. To ensure the suptly of such large quantities of lFV on a continuous basis, 
it 1a iaperative that the country produces this vaccine in sufficient 
quantity to aeet at least ita clomeatic requireiH!Ilta. 'l'his is so, because 
of the fact that such a large quantities of the vacc:ine will increase 
appreciably the coat of EPI. 
'lhe experta fJ:'OIR W!l) have strongly rec:otiiiRended the modernisation of streng-
t.bening of the YPY and production facilities at Yaba. 'l'his will involve 
the aanufacture of theriiOStable vac:cl.ne and the adoption of the rec:a.tended 
quality controJ requirements. 
11. 'l'he Federal Ministry of Health baa also aade a strong COIIIUitment to make 
investaents required to IIOdernize and to strengthen the YFV facilities. 
But, the external collaboration in all steps of this three-year project 
is of uttet11l0St i.Japortance, especially those related to the supporting of 
the training of local personnel abroad in a Yellow Fever Vaccine Producing 
Institution, providing new laboratory equipment, imported supplies and scaae 
stationery resources. 
OBJECTIVES 
12. The objectives of this project are: 
(a) to promote the modernization and the strengthening of Yellow Fev-er 
Vaccine Laboratory facilities at Yaba, Lagos. 
(b) to promote the adoption, in all steps of production and. quality 
control of Good Manufacturing Practices and to ensure their compliance 
with WHO Requirements. 
(c) to promote the up-grading of the vaccine production laboratory to 
manufacture increased quantities and improve the quality of the vac:clne 
with introduction of thermostable formulation. 
METHODOLOGY 
13. Initially, a critical evaluation of the facility was performed. An analysis 
of the flow of production, which included the appraisal of the condition of 
equipments, the evaluation of quality control system, the production and 
quality control procedures was carried out. 
14. To enable further actions for modernization to be taken, a preliminary 
drawing of the facility was prepared(attach. 1). It takes into account, 
whenever possible, the flow of production, avoiding cross aovements 
cOWlb.ining compatible activitie. and protectinq areas for sterile operations. 
In a separate bui.lding in the same compound, a drawing for a diluent 
production facility was also preparec:Usee attch.2). 
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15. A summary of this study waa also submitted to the authorities of 
Ministry of Health and a COIIIIlitment to support this project was 
assured. 
'l'he cost of moderni&ation has been estimated at US $49 000,000 
and will be largely supported by the Federal Ministry of Health. 
Already, an amount of about US $1,500,000 is being set aside for 
this project by the Federal Ministry of Health. 
U. To aate pouible the modernization of the facility at low cost, 
the proposal takes into account the existing walls of the 
present building with <JMy lftinor additions to be aade. 
Bearing in aind the nature of the lllOdernization envisaged, a new 
electrical wirin9 system, a centralised air-conditioninq systa, 
central steaJR generator, an over-head tank, replacf!llellt of existing 
water pipes and ineoporation of hot water supply will be required. 
An additional high capacity generator wi:th automatic switch systaa 
will also be required. 
17. In view of the present unfavourable econOilic situation of Nigeria, 
the expenditure on iaported equipaent, materials and supplies will 
be very difficult. Therefore external assistance to help in the 
acquisition of these it-. is strongly needed. A list of the ujor 
equipaent u vell as other needed materials and supplies is needed 
in the budget table. 
TRAINING 
18. The 'XFVPL, Yaba amploys 16 qraduates/profeuionals and has an 
adequate number of supporting staff. Durin<J the modernization 
period the production activities will be reduced to the min.i.mum. 
This period will be used for the training of selected technical 
and scientific staff abroad, preferably at Yellow Fever Vaccine 
producing laboratory or institution e.g. FIOCRUZ, Brazil. 
It is recommended that 9 members of staff would be trained or 
retrained on a recycling basis 1n the areas of YP vaccine production( 2) , 
aniaal breeding and testing( 4), Quality Control( 2), Microbiology( 1), 
Chemistry(1), Tissue Culture(4), Diluent production(1) and laboratory 
equipaent raaintenance(2). For these staff members, the period of 
tra.ininq will vary from 1-3 months. 
Additionally, the Direct:or(Consultant Virologist) and the WHO Con-
sultant Virologist attached to the project should make short visits 
to selected laboratories for the period of not less than 2 weeks. 
CONSULTANCY 
1.9. For the attainment of faster and effective results of the modernization 
and achievement of set goals, it is advisable to engage the services of 
consultants on various aspects, who will be visiting the facilities 
during the modernization and after upgrading. These consultants will 
be required in the areas of enqineering/maintenance and in the latest 
production and quality control technologies. It will be preferable 
if the consultants on production technology and control could come 
fran the institution where the FVPL staff will be trained. 
ADMINISTRATION AND BUDGET 
20. This 3-year project will be administered by the Federal Vaccine 
Production Laboratory of the Federal Ministry of Health. A special 
account will be opened in the name of the project in a bank, with 
the Permanent Secretary or his designated representative and the 
Head of the FVPL be co-signatories of the Cheques. 
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It is estimated that the cost of equipaent, materials will be 
CAN $585,600.00 and the supplies will be CAN $73,000.00. 
The training programme and conaultancy will cost CAN $130, soo. 00. 
'l'be money for the Stationery will be CAN $42,000.00. 
The total project value will be CAN $789.100.00. 
• 





(24 person - months) 
1-Princ:ipal Medical Lab. Technologist 
(36 person - months) 
2-Senior Medical Lab. 'rechnologist 
(36 person - months) 
8-Medieal Lab. Technologist 
(36 person - months) 
5-Scientific Officer 
( 36 person - month) 
2-Principal Maintenance Officer 
( 6 person - months) 
12-Lab. Assistance 
(36 person - months) 
to-Lab. Attendants 




4. Final Reports 
Total Recipient administered funds 
IDRC CONl'RIBUl'ION 
(IN CAN DOLLARS) 









- - -10,000 10,000 10,000 
3,000 3,000 3,000 
- - 3.000 
13,000 13,000 1.51 000 
NIGERIA MOH/FVPL( IN NAIRA H) 
TOTAL YEAR 1 YEAR 2 YEAR 3 Total 
7,400 7,400 7,400 22,600 
8,700 8,700 8,700 26,000 c 
14,000 14,000 14,000 42,000 
46,080 46,080 46,080 138,240 
22,620 22,620 22,620 67,860 
17,364 17,364 17,364 52,092 
20,880 20,880 20,880 62,640 L 
15,960 15,960 15,960 47,880 
1.53,004 153,004 153,004 459,0~2 
30,000 -40,000 40.000 40;000 1:20,000 
9,000 5!000 5,000 -5!000 15,000 
3~000 e.ooo e_.ooo ~.ooo 24.000 
42,000 201,004 206,004 206,004 6'18,0'12 
~ 
IDRC CO!fRimiOJ (CAlf) 
!0 U ADJIDISftUD BY IDRC ~- .tiU 1 
1, liUIBU:IITa 
1 Pne~er, plu aoeaaeriea aDCl 
.,... part. 160,000 
~\1 • PlllJ.Dc and atepper ••chine, plu •: 
aoe-ri•• a:nd apare parta 120,000 
1 A11toaatic vial wash IIS.Chiu, plus 
aoeueriea 87,000 
1 Betriprated eelltrihce, plua 
Rotor, aoeaaoriea and apare parta 18,000 
1 Reverse oa .. ae ~ater puri~icat1~ )$,000 
3 SuapeDded Vertical Laaiur new 
ua1 t, wi tb aoceaeeriee )8,000 
2 icg iDcubator ceaplete vi th automatic 
nYOlttrac 18,000 
........................... -..>ol"":-.•-- • 
·2 Wath cliatilater 7,000 
1 Shell rreesi.Dc ..ohine 2,000' 
J Steriliaiac even i 2,000 
1 Labell!Dg uchine {...S.-aut ... tio) 12,000 
2 lg oandliDC uohiDe s,ooo 
2 Aut.clave heris•tal 8,600 
·-2 "Deep Preezer - as•c with acceasori•·-· -
aD4 apan parta 20,000 
kperi.Mntal aniMl. cace• (ter 
~\:,~ pip, rabbi ta, llioe) plua 
- '8helfta, bettlea and. acoe-riea 16,000 
1 0 ... bile rack• tor oace 16,000 
. ' 
~·ftl-\er Belcler with aoeaHriea ~ ...... 10,000 ,. 
Sub Total S8S,6oo 
2. SUPPLIES 
- Span parta ter niaUraa equipaenta 10,000; 
"' - Glaaavare 10,()()()~ 
- Reapnta ancl .nia 2,000. 
- SbippiJac s.ooo 
·." 
Su~total 27,000 























































IDRC COJITRIBU'l'IOI (Cdg) COftD• 
1'0 BE ~DMI'IIS!EHED BY IDRC YEAR 1·' TEAB 2 TEAR) TOTAL 
). 'l'RAI!ll.NG 
-~ 
2 ;:-e.rdinater + WO Consultant 9,000 - - 9,000 
. ·:,aPriDoipal Jlle41cal Lab. Technelegiat 9,000 - - 9,000 
6-Senier Medical Lab. Techaelegiat 18,000 18,000 18,000 54,000 
2-Maiatenance - 18,000 - 18,000 
Sub-tetal )6,000 )6,000 18,000 90,000 
4. COISULTAJ! VISI!ING 
1-Preject develo~nt 4 '.'00 ,_ 4,500 4,500 1),$00 . 
1-&qllipnat ~taintenoce - I.Jt500 4,500 9,000 
1-Pre4uction operatien - 4,500 4,500 9,000 
1-Qulit7 C.ntrol - 4,500 4,500 9,000 
Sub-tetal 4,500 18,000 18,000 40,500 
TOTAL •• ••. •• •... 6531.101 77,000 S9,000 
Total IDRC a4111Diatered pertien CAl- 789,100.00 
Total J'VPL acbliD1atered portieD CAR- 42,000.00 
(Stat1oner"71 cOIIIIUilloation, final Report) . 
Total ef the project in Candian dellar• 
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